Abstract: Researchers at the Center for Public Genomics at Duke University analyzed how patenting and licensing affect clinical access to genetic testing in the United States. The research was requested by the Secretary's Advisory Committee on Genetics, Health, and Society. Conditions studied were breast and ovarian cancers, colon cancers, Alzheimer disease, cystic fibrosis, hearing loss, hereditary hemochromatosis, long QT syndrome, spinocerebellar ataxia, Tay-Sachs disease, and Canavan disease. Genet Med 2010:12(4):S1-S2.
T he case studies that follow were commissioned by the Secretary's Advisory Committee on Genetics, Health, and Society (SACGHS) and US Department of Health and Human Services.
In 2006, the SACGHS contacted the Center for Public Genomics (CpG) at Duke University for help in analyzing how patenting and licensing affect clinical access to genetic testing in the United States. SACGHS's interest grew largely from public controversies about breast and ovarian cancer, Canavan disease, and other "gene patents" associated with clinical genetic testing. Controversies in the 1990s led to policy reports around the world. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] In mid-2006, SACGHS appointed a task force to address the impact of patenting and licensing on clinical access to genetic testing, chaired by James P. Evans of the University of North Carolina. The capstone students prepared an analytical framework and "case studies" and presented preliminary findings to the SACGHS task force in March 2007. Two more case studies were added through the CpG summer student research program, including a study by undergraduate Katie Skeehan on testing for Alzheimer disease and by University of North Carolina graduate student Ashton Powell on spinocerebellar ataxia (SCA). CpG revised and augmented the student reports with patent landscapes and stakeholder interviews. From late 2006 until March 2009, CpG researchers studying the histories of seminal genomic technologies began working almost exclusively for SACGHS and its task force. Both the project officer for the grant that funds the CpG and the National Human Genome Research Institute Director were enthusiastic about having outputs of the CpG's research be inputs to SACGHS and agreed with reorienting the research priorities of the CpG to accommodate the needs of SACGHS.
The CpG-SACGHS collaboration depended on the work of many people for several years. The case studies also leveraged the network of experts associated with the grant. The SACGHS case studies were critiqued at annual CpG retreats, CpG monthly investigator meetings, and Duke-wide Institute for at the SACGHS's October 8 -9 meeting in 2009, when the case studies were referred to during the debate. 11 With the exception of updates to prices and patent information, as noted in the text, and to the long QT and breast and ovarian cancer case studies and formatting changes, the case studies are published in Genetics in Medicine in the same form as they were released for public comment.
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